康緣藥業(600557.SH):筋骨止痛凝膠納入國家醫保目錄
格隆匯12月28日丨康緣藥業(600557.SH)公佈,2020年12月28日,國家醫保局、人力資源社會保障部發布了《關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年)>的通知》(醫保發〔2020〕53號),根據該通知,公司藥品筋骨止痛凝膠經談判納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年)》。筋骨止痛凝膠支付標準:55元,規格:15g/支。
公司表示,筋骨止痛凝膠為公司今年新獲批上市藥品,暫未進行批量生產和銷售。因該品種為公司獨家品種,且給藥途徑具有優勢,此次經談判被納入《國家醫保目錄》後,預計未來將對銷售起到積極的作用,但短期內不會對公司的業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.